Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 17/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4510290 | 1.00 | F10 (0.47) | F10HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4492482 | 0.94 | F10 (0.54) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4516534 | 0.93 | F10 (0.46) | F10HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4516536 | 0.92 | F10 (0.47) | F10HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4505523 | 0.90 | F10 (0.50) | F10HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4505526 | 0.90 | F10 (0.50) | F10HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4505578 | 0.90 | F10 (0.48) | F10HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4505576 | 0.90 | F10 (0.48) | F10HTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4502528 | 0.89 | F10 (0.46) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4515930 | 0.85 | F10 (0.55) | F10CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | claimed |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-7615549-B2 | Substituted pyrrolidinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-11-10 | — | — | US | disclosed |
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142263-A1 | NEW SUBSTITUTED PYRROLIDINONES, THEIR MANUFACTURE AND THEIR USE AS MEDICAMENTS | PYCR1, OAT, UROD | F10 814/4885HTT 2738/4885CYP1A2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.